Background
Teriflunomide (also known as A77 1726), the active metabolite of an approved antirheumatic drug Leflunomide, is an emerging oral therapy for multiple sclerosis (MS). Teriflunomide has demonstrated anti-inflammatory, antiproliferative and immunosuppressive
动态评分
0.0